Datasea Inc.DTSSNASDAQ

52-Week Range1-3

0.64Current 0.932.80

Want to monitor DTSS?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Gross Margin

Operating Margin

Revenue Growth

datasea has an ad-hoc query and reporting engine that uses a simple, search-like interface.

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

News

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

Aflac celebrates 20 years as a World's Most Ethical Company

Mosaic's Rare Earths Bet Could Revalue the Stock: What That Means for Investors

Truist announces first quarter 2026 earnings call details

AirSculpt Technologies Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

FLUENT Corp. Announces Amendment to Senior Secured Credit Agreement

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Steer Clear Of The Braiin AI Listing

Spectral Capital on Track to Meet or Exceed 2026 Revenue Guidance of $450 Million with Over $200 Million Generated in First Two Months of the Year

Boyd Group Services Inc. (BGSI) Q4 Earnings Top Estimates

Docusign: Stabilizing Business At A Great Price

Jabil Lifts Outlook as Profit, Revenue Rise

TransUnion Strengthens Device Security with New Machine Learning Capabilities

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

PepsiCo Named Official Beverage Partner of VENU's Premium Sunset Amphitheater Portfolio

uCloudlink Group Inc. Sponsored ADR (UCL) Reports Q4 Loss, Misses Revenue Estimates

2 Stocks I'm Buying for the Future of AI Work

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

NAPC Defense, Inc. Positioned as Primary Subcontractor on Obera Portfolio Following Asset Acquisition by Native American Pride Constructors, LLC

About